anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In two randomized placebo-controlled trials of 2 years duration in patients with mild cognitive impairment (MCI), a total of 13 patients on galantamine (n=1026) and 1 patient on placebo (n=1022) died. The deaths were due to various causes which could be expected in an elderly population; about half of the galantamine deaths appeared to result from various vascular causes (myocardial infarction, stroke, and sudden death).  
  
Although the difference in mortality between galantamine- and placebo-treated groups in these two studies was significant, the results are highly discrepant with other studies of galantamine. Specifically, in these two MCI studies, the mortality rate in the placebo-treated patients was markedly lower than the rate in placebo-treated patients in trials of galantamine in Alzheimer’s disease or other dementias (0.7 per 1000 person years compared to 22 to 61 per 1000 person years, respectively). Although the mortality rate in the galantamine-treated MCI patients was also lower than that observed in galantamine-treated patients in Alzheimer’s disease and other dementia trials (10.2 per 1000 person years compared to 23 to 31 per 1000 person years, respectively), the relative difference was much less. When the Alzheimer’s disease and other dementia studies were pooled (n=6000), the mortality rate in the placebo group numerically exceeded that in the galantamine group. Furthermore, in the MCI studies, no patients in the placebo group died after 6 months, a highly unexpected finding in this population.  
  
Individuals with mild cognitive impairment demonstrate isolated memory impairment greater than expected for their age and education, but do not meet current diagnostic criteria for Alzheimer’s disease.
APG-1387 is a potent, bivalent small-molecule IAP antagonist. This study is multi-center, single-agent, open-label, Phase I dose-escalation study of APG-1387.

This study has a 4-dose-schedule which is escalated one by one after confirming safety in the previous lower dose schedule. A total of 60 subjects with Chronic Hepatitis B will be participated in the study. APG-1387 will be administrated via intravenous infusion, once a week for consecutive 4 weeks as one cycle.The start dose is 7mg. 3 patients' cohorts will be evaluated, the dose of APG-1387 will be increased in subsequent cohorts, to 12mg, 20 mg, 30 mg, 45 mg accordingly. 3 patients in 7mg,12mg cohorts and 6 patients in 20mg, 30mg and 45mg cohorts will be recruited. If there is any one of the following event is observed within 28 days of the first dose of APG-1387, the recruitment will be hold and a discussion on MTD dose level will happened.1 ≥1/2 patients experience ≥Grade 2 toxicities\[CTCAE 4.0.3\] related or possibly related with APG-1387 and with clinical manifestation. 2 ≥1/3 patients experience ≥Grade 3 toxicities\[CTCAE 4.0.3\] related or possibly related with APG-1387.3 any SAE related or possibly related with APG-1387. Expansion study will be designed to explore primary efficacy and safety after the dose escalation study. The expansion number and dosage will be decided according to the results of each cohort.(no more than 36 patients).
BACKGROUND: Conservative care (CC) is a viable treatment option for some patients with kidney failure. Choosing between dialysis and CC can be a complex decision in which involvement of patients is desirable. Gaining insight into the experiences and preferences of patients regarding this decision-making process is an important initial step to improve care. We aimed to identify what is known about the perspective of patients regarding decision-making when considering CC.
METHODS: PubMed, EMBASE and Cochrane databases were systematically searched on 23 February 2023 for qualitative and quantitative studies on patient-reported experiences on decision-making about CC. Data were analysed thematically.
RESULTS: Twenty articles were included. We identified three major themes: creating awareness about disease and treatment choice, decision support and motivation to choose CC. Patients were often not aware of the option to choose CC. Patients felt supported by their loved ones during the decision-making process, although they perceived they made the final decision to choose CC themselves. Some patients felt pressured by their healthcare professional to choose dialysis. Reported reasons to choose CC were maintaining quality of life, treatment burden of dialysis, cost and the desire not to be a burden to others. In general, patients were satisfied with their decision for CC.
CONCLUSIONS: By focussing on the perspective of patients, we identified a wide range of patient experiences and preferences regarding the decision-making process. These findings can help to improve the complex decision-making process between dialysis and CC and to provide patient-centred care.
Fluorescent compositions with enhanced fluorescent intensity are provided. Methods for using the fluorescent compositions in medical imaging are also provided. The enhanced fluorescent compositions can be a mixture or solution comprising a fluorescent dye and a light-scattering emulsion or fluorescence-enhancing diluent. The fluorescent dye, e.g., indocyanine green (ICG), is activated by near-infrared radiation. The fluorescence-enhancing diluent can be milk, infant formula, intravenous fat emulsions, soy bean oil, egg phospholipids, Intralipid, Liposyn, Nutralipid, Soyacal, Travamulsion, SMOFlipid, Clinoleic, Lipovenoes and/or combinations thereof. The fluorescent intensity of the enhanced fluorescent composition can be 5 to 20 or more times greater than that of the fluorescent dye in solution without added fluorescence-enhancing diluent.
PURPOSE: To provide a composition for skins which contains, as an active ingredient, an extract of Phyllanthus niruri, a plant belonging to Euphorbia, growing in the subtropical and tropical zones of the Central and Southern Americas, thus is excellent in anti-aging effect and useful as a living body-antiaging agent with high safety. CONSTITUTION: This living body anti-aging agent contains an extract from the roots, leaves, stems, ground stems and flowers with water or an organic solvent. When the extraction solvent is nontoxic such as water, ethanol or ethanol-water, the extract may be directly applied. Further, it may be diluted or concentrated. The extract may be processed into a dried powder by freeze- drying or into paste. Since antiaging agent contains an extract of Phyllanthus niruri, this antiaging agent gives the cells and tissues activation action to develop high living body-anti-aging activity with safety increased and inhibit the aging of skin.
The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a physical form that potentially inhibits (e.g. does not permit easy) access of iron sequestered by the compositions to the cells being targeted. Compositions comprising chelating aspects affixed to or incorporated into suitable carrier materials such that the resulting metal chelating composition is soluble in aqueous media are also provided. Disclosed herein are chelating compositions, for chelating one or more essential metals. The chelating compositions being soluble in an aqueous medium and comprising one or more metal binding chemical groups affixed to or incorporated into the structure of a carrier material, such that the resulting chelating composition is able to bind one or more metals, and remains substantially soluble in the aqueous medium with its bound metal or metals.
In France, about 130,000 persons per year are victims of stroke. Thirty percent of the victims suffer from aphasia during the acute phase. These language impairments have an impact on caregiving. In the context of post-stroke aphasia, the most relevant means of verbal communication is closed-ended questioning. However, the available tools do not allow a professional consensus and the comprehensive assessment tools for aphasia do not provide any indication of the reliability of patients' answers. The investigators have developed a tool, the yes/no questionnaire that consists of 10 closed-ended questions designed to assess the patient's ability to provide a coherent answer. During one year, successive patients taken care in the neurovascular unit at la Rochelle hospital will be assessed for eligibility to the study and their relative will be informed and ask for consent. Aphasic patients will therefore answer the yes/no questionnaire. Based on the speech therapist evaluation, patients will be classified as "reliable respondent" or "unreliable respondent".
OBJECTIVES: Gentamicin is one of the most common ototoxic drugs that can lower patients' quality of life. Oxidative stress is a key factors inducing sensory hair cell death during gentamicin administration. So far, there are no effective drugs to prevent or treat gentamicin- induced hearing loss. A recent study found cystic fibrosis transmembrane conductance regulator (CFTR) as a new target to modulate cellular oxidative balance. The objective of this study was to estimate the effect of the CFTR activator ivacaftor on gentamicin-induced ototoxicity and determine its mechanism.
METHODS: The hair cell count was analyzed by Myosin 7a staining. Apoptosis was analyzed by TUNEL Apoptosis Kit. Cellular reactive oxygen species (ROS) level was detected by DCFH-DA probes. The Nrf2 related proteins expression levels were analyzed by western blot.
RESULTS: An in vitro cochlear explant model showed that gentamicin caused ROS accumulation in sensory hair cells and induced apoptosis, and this effect was alleviated by pretreatment with ivacaftor. Western blotting showed that ivacaftor administration markedly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO1), and NAD(P)H:quinone oxidoreductase 1 (NQO1). The protective effect of ivacaftor was abolished by the Nrf2 inhibitor ML385.
DISCUSSION: Our results indicate the protective role of the CFTR-Nrf2-HO1/NQO1 pathway in gentamicin-induced ototoxicity. Ivacaftor may be repositioned or repurposed towards aminoglycosides-induced hearing loss.
A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method is useful in treating dry eye diseases. The method is also useful in reducing contact lens intolerance in the eyes. The method comprises administering to the eyes of a subject in need thereof a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form, injectable, intra-operative instillation or suppository form.
FIELD: biotechnology, microbiology, medicine, obstetrics-gynecology. SUBSTANCE: strain is isolated from vagina of health woman of reproductive age. Strain is able to inhibit opportunistic microorganisms in vitro and in vivo effectively, it produces acids and shows expressed adhesion to vaginal epitheliocytes. Strain Bifidobacterium longum Z4 shows absence of pathogenicity and pyrogenicity for humans and animals, it normalizes microflora in women genital way. Strain can be used as the preparation-probiotic for correction of disorders of microbiocenosis in women genital way. EFFECT: strain indicated above, enhanced curative effectiveness of strain. 2 tbl, 3 ex
The invention discloses a feed additive capable of preventing and treating fatty liver syndromes of laying hens. The feed additive consists of the following raw materials in parts by weight: 15-30 parts of raw haws, 15-25 parts of rhizoma alismatis, 15-25 parts of fleeceflower roots, 10-15 parts of semen cassiae, 5-10 parts of radix salviae miltiorrhizae, 5-10 parts of radix polygonati officinalis, 1-2 parts of niacin and 5-8 parts of choline chloride. The invention further discloses a preparation method and the application of the feed additive. According to the feed additive disclosed by the invention, ultra-fine pulverization is more favorable of the release and the absorption of medicines than common pulverization, and biological availability and medicinal effects are improved. According to the traditional Chinese veterinary medicine theory of Chine, six kinds of Chinese herbal medicine materials are selected and are compounded with vitamins according to a preferable compounding ratio so that the feed additive is prepared; compared with other additives, the feed additive disclosed by the invention is more obvious in the effects, free from side effects and free from medicinal residues. The feed additive disclosed by the invention is small in addition quantity, low in cost and convenient to produce and use.
The aim of this study is to investigate the adverse effects of benzophenones (BPs) on the intestinal tract of mice and the potential mechanism. F1-generation ICR mice were exposed to BPs (benzophenone-1, benzophenone-2, and benzophenone-3) by breastfeeding from birth until weaning, and by drinking water after weaning until maturity. The offspring mice were executed on postnatal day 56, then their distal colons were sampled. AB-PAS staining, HE staining, immunofluorescence, Transmission Electron Microscope, immunohistochemistry, Western Blot and RT-qPCR were used to study the effects of BPs exposure on the colonic tissues of offspring mice. The results showed that colonic microvilli appeared significantly deficient in the high-dose group, and the expression of tight junction markers Zo-1 and Occludin was significantly down-regulated and the number of goblet cells and secretions were reduced in all dose groups, and the expression of secretory cell markers MUC2 and KI67 were decreased, as well as the expression of intestinal stem cell markers Lgr5 and Bmi1, suggesting that BPs exposure caused disruption of intestinal barrier and imbalance in the composition of the intestinal stem cell pool. Besides, the expression of cellular inflammatory factors such as macrophage marker F4/80 and tumor necrosis factor TNF-α was elevated in the colonic tissues of all dose groups, and the inflammatory infiltration was observed, which means the exposure of BPs caused inflammatory effects in the intestinal tract of F1-generation mice. In addition, the contents of Notch/Wnt signaling pathway-related genes, such as Dll-4, Notch1, Hes1, Ctnnb1and Sfrp2 were significantly decreased in each high-dose group (P < 0.05), suggesting that BPs may inhibit the regulation of Notch/Wnt signaling pathway. In conclusion, exposure to BPs was able to imbalance colonic homeostasis, disrupt the intestinal barrier, and trigger inflammation in the offspring mice, which might be realized through interfering with the Notch/Wnt signaling pathway.
Foreseen as foundational in forthcoming oncology interventions are multimodal therapeutic systems. Nevertheless, the tumor microenvironment (TME), marked by heightened glucose levels, hypoxia, and scant concentrations of endogenous hydrogen peroxide could potentially impair their effectiveness. In this research, two-dimensional (2D) Ti3C2 MXene nanosheets are engineered with CeO2 nanozymes and glucose oxidase (GOD), optimizing them for TME, specifically targeting cancer therapy. Following our therapeutic design, CeO2 nanozymes, embodying both peroxidase-like and catalase-like characteristics, enable transformation of H2O2 into hydroxyl radicals for catalytic therapy while also producing oxygen to mitigate hypoxia. Concurrently, GOD metabolizes glucose, thereby augmenting H2O2 levels and disrupting the intracellular energy supply. When subjected to a near-infrared laser, 2D Ti3C2 MXene accomplishes photothermal therapy (PTT) and photodynamic therapy (PDT), additionally amplifying cascade catalytic treatment via thermal enhancement. Empirical evidence demonstrates robust tumor suppression both in vitro and in vivo by the CeO2/Ti3C2-PEG-GOD nanocomposite. Consequently, this integrated approach, which combines PTT/PDT and enzymatic catalysis, could offer a valuable blueprint for the development of advanced oncology therapies.
A method for depositing films of a fluorinated compound is disclosed, wherein a reactive sputtering process allows the use of a metal or other non-fluorinated material as the target material. The process developed also utilizes XeF 2  as a vapor source, which provides fluorine for the formation of the fluorinated compound. Unlike reactive process gases, such as SF 4  and CF 4 , used in previous experiments attempting reactive sputtering of fluoride compounds, the XeF 2  vapor does not result in unwanted contamination due to a reactive gas cation, i.e., inclusions of carbon or sulfur. These, and other considerations, have allowed the development of a process for fabricating dense, optical quality fluoride films. At the same time, the material costs and handling expenses related to the XeF 2  source are also relatively low. The method described is ideally suited for the deposition of metal fluoride compounds for use in anti-reflection coatings, UV optical coatings, as well as various applications in the semiconductor, optoelectronics, and other industries.
Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
The ARTORIA-R is an international, observational research project collecting retrospective data from 18 countries in the period 1989 to 2024 and will thereafter include data prospectively (Figure 1). These data include patient profiles at time of evaluation for listing, listing, waiting list dynamics, post-transplant data and basic donor data. Future data will be updated annually in July each year and each institution willing to contribute anonymised data to the register is invited to participate. Furthermore, the institutions and organ allocation agencies have to obtain a positive vote of the ethic committee responsible for the data transmission of anonymized patient data.

The inclusion criteria are: a. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years b. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD c. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation d. Transfer of anonymised data e. The institution/organization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions. The registry has the aim to achieve meticulous information regarding the underlying congenital heart defect and the previous treatment of the patient. With these information the patients can be divided into different cohorts with a systemic left ventricle, a systemic right ventricle or a single ventricle (which can be either an anatomic left or right ventricle). Further data is acquired regarding the medical treatment, the haemodynamic evaluation of the patient, laboratory testing to assess additional organ function of the kidney or liver, treatment in the intermediate care or intensive care unit. As it is of special relevance in ACHD patient treatment of arrhythmia, antiarrhythmic medication and use of ICD or cardiac resynchronization therapy are evaluated. Were available the data regarding imaging at listing with ejection fraction for the systemic ventricle with echocardiography or cardiac magnetic resonance imaging are obtained.

The exclusion criteria is: a. The patient is listed for a second heart transplantation (retransplantation) During the ongoing study additional institutions and organizations will be asked to include their data as well. Although the initial data is retrospective additional data into the register will be entered prospectively.
PROBLEM TO BE SOLVED: To obtain a film forming-type pack material improving the effect of removing a horny plug and an aged keratin by blending fine particles of a metal oxide having specific diameters in a non surfactant system for adsorbing the fine particles of the metal oxide to the surface of a skin effectively. SOLUTION: This film forming-type pack material is obtained by blending fine particles of a metal oxide having its mean primary particle diameter in a range of 5-100nm without using any surfactant. As the metal oxide, e.g. titanium oxide, zinc oxide, iron oxide, iron hydroxide, anhydrous silicic acid, etc. are used, and the amount of blending is preferably approximately 5-20wt.% based on 100 pts.wt. of the film forming pack material. As the film forming agent in this pack material, a polyvinyl alcohol is the most suitable.
FIELD: veterinary science. SUBSTANCE: the present innovation deals with preparations of prolonged action for treating animal diseases caused by bacteria and chlamydia. The suggested antibacterial composition contains either tylosin or its derivative, additional substance phthaloylgelatin at 5 : 1 ratio, correspondingly, and water at the following ratio of components, weight%: tylosin (tylosin derivative) 5-10, additional substance 1-2, water the rest. Composition is of high therapeutic effect at treating respiratory and gastrointestinal diseases and necrobacteriosis in cattle. EFFECT: higher efficiency of therapy. 4 ex, 3 tbl
The invention relates to a traditional Chinese medicine oral liquid for treating gosling plague and a preparation method of the traditional Chinese medicine oral liquid. The traditional Chinese medicine oral liquid is prepared from red halloysite, dried ginger, polished round-grained rice, kudzu vine roots, ephedra, asarum, fructus evodiae, dates, liquorice and monkshood. The traditional Chinese medicine oral liquid can be an oral liquid. The preparation method comprises the following steps: (1) crushing the traditional Chinese medicines to be 60-80 meshes, weighing according to the formula portions, and mixing in a three-dimensional manner, thereby obtaining traditional Chinese medicine powder; (2) respectively feeding the mixed traditional Chinese medicine powder and 300-600 parts of water into an extraction tank to soak for 5-20 hours; (3) heating to 40-100 DEG C, and extracting for 10-15 hours; (4) filtering and collecting decoction; (5) continuously adding 300-600 parts of water into the residual decoction dregs, and extracting for 10-15 hours at 40-100 DEG C; (6) filtering to remove the decoction dregs, combining the extraction liquids, and performing vacuum concentration at 30-70 DEG C until the volume is 10-20% of the original volume; and (7) filling 250ml of the liquid into one bottles respectively, thereby obtaining a finished product. The traditional Chinese medicine oral liquid provided by the invention can be used for effectively treating gosling plague, and the recovery rate can be greater than 90%. The traditional Chinese medicine oral liquid has the effects of warming the middle warmer and relieving exterior syndromes, astringing intestine to stop diarrhea and astringing to stop bleeding.